Trial · NCT04120194
Results by group108
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 108
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| HAI Antibody Responses for Vaccine Homologous Influenza Strains Expressed as Ratio of Geometric Mean Fold Ratio (GMFR) | NanoFlu | A/Brisbane/02/2018 (H1N1) | 1.9 | 95% Confidence Interval 1.8 to 2.0 | Geometric Mean Fold Ratio |
| HAI Antibody Responses for Vaccine Homologous Influenza Strains Expressed as Ratio of Geometric Mean Fold Ratio (GMFR) | Fluzone Quadrivalent | A/Brisbane/02/2018 (H1N1) | 1.7 | 95% Confidence Interval 1. to 1.8 | Geometric Mean Fold Ratio |
| HAI Antibody Responses for Vaccine Homologous Influenza Strains Expressed as Ratio of Geometric Mean Fold Ratio (GMFR) | NanoFlu | A/Kansas/14/2017 (H3N2) | 2.7 | 95% Confidence Interval 2.6 to 2.9 | Geometric Mean Fold Ratio |
| HAI Antibody Responses for Vaccine Homologous Influenza Strains Expressed as Ratio of Geometric Mean Fold Ratio (GMFR) | Fluzone Quadrivalent | A/Kansas/14/2017 (H3N2) | 2.3 | 95% Confidence Interval 2.2 to 2.4 | Geometric Mean Fold Ratio |
| HAI Antibody Responses for Vaccine Homologous Influenza Strains Expressed as Ratio of Geometric Mean Fold Ratio (GMFR) | NanoFlu | B/Maryland/15/2016 (Victoria lineage) | 1.6 | 95% Confidence Interval 1.5 to 1.6 | Geometric Mean Fold Ratio |
| HAI Antibody Responses for Vaccine Homologous Influenza Strains Expressed as Ratio of Geometric Mean Fold Ratio (GMFR) | Fluzone Quadrivalent | B/Maryland/15/2016 (Victoria lineage) | 1.5 | 95% Confidence Interval 1.5 to 1.6 | Geometric Mean Fold Ratio |
| HAI Antibody Responses for Vaccine Homologous Influenza Strains Expressed as Ratio of Geometric Mean Fold Ratio (GMFR) | NanoFlu | B/Phuket/3073/2013 (Yamagata lineage) | 2.4 | 95% Confidence Interval 2.3 to 2.5 | Geometric Mean Fold Ratio |
| HAI Antibody Responses for Vaccine Homologous Influenza Strains Expressed as Ratio of Geometric Mean Fold Ratio (GMFR) | Fluzone Quadrivalent | B/Phuket/3073/2013 (Yamagata lineage) | 2.0 | 95% Confidence Interval 1.9 to 2.1 | Geometric Mean Fold Ratio |
| Mean Difference in the Seroconversion Rate (SCR) HAI Antibody Responses for Vaccine Homologous Influenza Strains Expressed as a Percentage of Participants | NanoFlu | A/Brisbane/02/2018 (H1N1) pdm09 | 22.0 | 95% Confidence Interval 19.8 to 24.4 | percentage of participants |
| Mean Difference in the Seroconversion Rate (SCR) HAI Antibody Responses for Vaccine Homologous Influenza Strains Expressed as a Percentage of Participants | Fluzone Quadrivalent | A/Brisbane/02/2018 (H1N1) pdm09 | 17.0 | 95% Confidence Interval 15.0 to 19.2 | percentage of participants |
| Mean Difference in the Seroconversion Rate (SCR) HAI Antibody Responses for Vaccine Homologous Influenza Strains Expressed as a Percentage of Participants | NanoFlu | A/Kansas/14/2017 (H3N2) | 41.8 | 95% Confidence Interval 39.1 to 44.6 | percentage of participants |
| Mean Difference in the Seroconversion Rate (SCR) HAI Antibody Responses for Vaccine Homologous Influenza Strains Expressed as a Percentage of Participants | Fluzone Quadrivalent | A/Kansas/14/2017 (H3N2) | 34.4 | 95% Confidence Interval 31.8 to 37.1 | percentage of participants |
| Mean Difference in the Seroconversion Rate (SCR) HAI Antibody Responses for Vaccine Homologous Influenza Strains Expressed as a Percentage of Participants | NanoFlu | B/Maryland/15/2016 (Victoria lineage) | 11.2 | 95% Confidence Interval 9.5 to 13.0 | percentage of participants |
| Mean Difference in the Seroconversion Rate (SCR) HAI Antibody Responses for Vaccine Homologous Influenza Strains Expressed as a Percentage of Participants | Fluzone Quadrivalent | B/Maryland/15/2016 (Victoria lineage) | 10.7 | 95% Confidence Interval 9.0 to 12.5 | percentage of participants |
| Mean Difference in the Seroconversion Rate (SCR) HAI Antibody Responses for Vaccine Homologous Influenza Strains Expressed as a Percentage of Participants | NanoFlu | B/Phuket/3073/2013 (Yamagata lineage) | 31.3 | 95% Confidence Interval 28.8 to 33.9 | percentage of participants |
| Mean Difference in the Seroconversion Rate (SCR) HAI Antibody Responses for Vaccine Homologous Influenza Strains Expressed as a Percentage of Participants | Fluzone Quadrivalent | B/Phuket/3073/2013 (Yamagata lineage) | 22.9 | 95% Confidence Interval 20.6 to 25.3 | percentage of participants |
| Number of Subjects With Solicited Local and Systemic Adverse Events (AEs) | NanoFlu | Local solicited TEAEs | 372 | participants | |
| Number of Subjects With Solicited Local and Systemic Adverse Events (AEs) | Fluzone Quadrivalent | Local solicited TEAEs | 243 | participants | |
| Number of Subjects With Solicited Local and Systemic Adverse Events (AEs) | NanoFlu | Systemic Solicited TEAEs | 369 | participants | |
| Number of Subjects With Solicited Local and Systemic Adverse Events (AEs) | Fluzone Quadrivalent | Systemic Solicited TEAEs | 292 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04120194/results